Rural Smoking Cessation

What Was Tested

In this not phased trial, researchers set out to test Therapeutic nicotine (patch, non-peptide).

Understanding ways to help people who live in rural areas quit smoking is a public health priority. quitting smoking among rural people who smoke is a critical public health concern.

It had three arms (groups): Intervention Condition (experimental), Control Condition (no intervention) and RHE - Intervention Condition (no intervention).

Weekly text and email messages referring to Smokefree.gov.

The registry classes the interventions as drug.

More on the Plan

This is a SMART, where eligible rural people who smoke (RPWS) can be randomized up to two times to different resources/ways to help quit smoking.

For each randomization, participants will use the assigned resources for 3 months, and partake in surveys at baseline, 1, and 3 months, during which they will be asked several questions related to use of resources, and smoking behavior.

Who Took Part

544 planned participants were the target.

It was open to people of any sex aged from 21 years with no upper age limit.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: ≥ 21 years. Smoke ≥ 5 cigarettes per day. Daily access to their own iPhone/Android smartphone or tablet.

The full record lists 3 inclusion and 2 exclusion criteria; among the exclusions: past 30-day nrt use or contraindications listed on the nrt labels; currently pregnant/breastfeeding.

How the Study Was Run

The set-up was randomized, parallel-group and single-blind.

Random assignment meant chance, not the researchers, decided who got Therapeutic nicotine (patch, non-peptide) and who got the comparison, which limits bias.

Groups ran in parallel: each of the participants stayed in one arm throughout.

In this single-blind Therapeutic nicotine (patch, non-peptide) study one party knew the assignments and the other did not.

Those kept unaware of assignments: participant.

It started in 2026-03-17 with completion listed for 2028-10-01.

It ran at 1 site in United States.

Its stated primary purpose is prevention.

What Was Measured

Researchers chose this as the main measure: Number of participants abstinent from all combustible tobacco products (time frame: 3 months).

It also tracked 1 secondary outcome, for example Cigarettes per day (CPD).

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of Therapeutic nicotine (patch, non-peptide) in 544 people.

With 544 participants it is a large trial for this field.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.